Vigonvita Life Sciences Co., Ltd. (SEHK: 2630)
Health Care · Pharmaceuticals · CN
HK$91.90
-20.50% today · +12.1% 1Y
Vigonvita Life Sciences Co., Ltd. (SEHK: 2630) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.96B and employs 315 people.
Over the last twelve months the share price has gained 12.1%, trading between 51.00 and 134.90.
Tweenvest scores Vigonvita Life Sciences Co., Ltd. across four factors: quality 33/100. Its strongest factor is quality.
2630 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.96B
- Revenue (TTM)
- $14.60M
- P/E
- —
- EPS
- -2.33
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$134.90
- 52-week low
- HK$51.00
- Avg volume (3M)
- —
- Shares outstanding
- 167.60M
- Employees
- 315
- Next earnings
- —
About Vigonvita Life Sciences Co., Ltd.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.
- Founded
- 2013
- Listed since
- Nov 6, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.